NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 44.6% and is now trading at $21.17. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) issued its earnings results on Thursday, May, 7th. The company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.77. The business had revenue of $22.38 million for the quarter, compared to the consensus estimate of $1.30 million. NextCure had a negative return on equity of 7.12% and a negative net margin of 65.22%. View NextCure's earnings history.

9 brokers have issued 12 month price targets for NextCure's shares. Their forecasts range from $40.00 to $87.00. On average, they anticipate NextCure's stock price to reach $64.67 in the next twelve months. This suggests a possible upside of 205.5% from the stock's current price. View analysts' price targets for NextCure.

Press coverage about NXTC stock has trended negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NextCure earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the stock's share price in the immediate future. View the latest news about NextCure.

Some companies that are related to NextCure include Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Xencor (XNCR), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Myovant Sciences (MYOV), Ligand Pharmaceuticals (LGND) and Aurinia Pharmaceuticals (AUPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $21.17.

NextCure has a market capitalization of $582.60 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]